COVID-19 and Cancer: Six MSK Physicians Discuss Innovations in Cancer Care during the COVID Crisis

COVID-19 and Cancer: Six MSK Physicians Discuss Innovations in Cancer Care during the COVID Crisis Banner

Add to Calendar COVID-19 and Cancer: Six MSK Physicians Discuss Innovations in Cancer Care during the COVID Crisis 8/11/2020 6:00:00 PM 8/11/2020 9:00:00 PM America/New_York Online false MM/DD/YYYY


Date & Location
Tuesday, August 11, 2020, 6:00 PM - 9:00 PM, Online, (EST) New York, NY

Overview

Important Announcement:
Registration for this event has reached capacity and is currently closed.
We will be recording this event and the materials will be available on-demand shortly. Please email cme@mskcc.org if you have any questions. 

This CME event will focus on six key areas in which the COVID-19 pandemic has prompted previously unasked questions regarding cancer treatments; including whether cancer surgery is essential or elective; and what effect cancer treatments have on COVID-19 patients. Other topics cover virology, epidemiology and therapeutics; and biotechnology and telemedicine in the quest to continue providing cancer care while keeping pace with an unpredictable, rapidly developing, and widespread disease.

 

Topics and Objectives

Lessons Learned in the Critical Care Management of COVID-19 Patients
Neil A. Halpern, MD, MCCM, FCCP, FACP

  • Determine how to rapidly approach a strange, new and unpredictable critical illness
  • Learn how to accommodate rapidly expanding ICU capacity
  • Understand the benefits of a robust ICU informatics infrastructure

Is Cancer Surgery Elective and The Impact of COVID-19 on Surgical Outcomes
Jeffrey Drebin, MD, PhD

  • Understand differences between elective and essential surgery and approaches to surgical triage at times of resource limitations
  • Recognize the impact of surgical treatment delay on outcomes for different types of solid tumors
  • Understand the impact of perioperative COVID-19 on the morbidity and mortality of cancer surgery.

SARS-CoV-2 Virology, Epidemiology and Therapeutics
 Tobias M. Hohl, MD, PhD

  • Understand the basic mechanisms of viral transmission
  • Define the mechanisms for entry of the virus and pathophysiology
  • Define therapeutic options and studies for treatment of SARS-CoV-2

COVID-19 Prevention, Health Care Worker and Patient Safety, and Testing
 Mini Kamboj, MD

  • Discuss available literature on testing and appropriate PPE in the health care environment and outcomes
  • Review contact tracing efforts, goals and outcomes
  • Discuss available literature on testing for patients and safety

Impact of Cancer Care on COVID-19 Outcomes
 Elizabeth V. Robilotti, MD, MPH

  • Review available data of COVID-19 severity in the hospitalized cancer patient including number ICU patients
  • Define risk factors for the severity of COVID-19 illness
  • Define severity of COVID-19 illness in cancer patient based on treatment modality including chemotherapy, targeted treatments, and immune-check point inhibitors

Caring for the COVID-19 Patient Through Cohort Monitoring and Telemedicine and Resuming Treatment for Recovered COVID-19 Patients
Diane Reidy-Lagunes, MD

  • Define how to care for the COVID-19 positive patient in the outpatient setting using biotechnology, telemedicine, and a cohort monitoring team approach
  • Define consensus guidelines on which patients to test for COVID-19 prior to treatment with antineoplastic therapy
  • Review consensus guidelines for resumption of antineoplastic therapy after the recovery of COVID-19 in the cancer patient
 


Objectives
  1. Determine how to rapidly approach a strange, new and unpredictable critical illness
  2. Learn how to accommodate rapidly expanding ICU capacity
  3. Understand the benefits of a robust ICU informatics infrastructure
  4. Understand differences between elective and essential surgery and approaches to surgical triage at times of resource limitations
  5. Recognize the impact of surgical treatment delay on outcomes for different types of solid tumors
  6. Understand the impact of perioperative COVID-19 on the morbidity and mortality of cancer surgery.
  7. Understand the basic mechanisms of viral transmission
  8. Define the mechanisms for entry of the virus and pathophysiology
  9. Define therapeutic options and studies for treatment of SARS-CoV-2
  10. Discuss available literature on testing and appropriate PPE in the health care environment and outcomes
  11. Review contact tracing efforts, goals and outcomes
  12. Discuss available literature on testing for patients and safety
  13. Review available data of COVID-19 severity in the hospitalized cancer patient including number ICU patients
  14. Define risk factors for the severity of COVID-19 illness
  15. Define severity of COVID-19 illness in cancer patient based on treatment modality including chemotherapy, targeted treatments, and immune-check point inhibitors
  16. Define how to care for the COVID-19 positive patient in the outpatient setting using biotechnology, telemedicine, and a cohort monitoring team approach
  17. Define consensus guidelines on which patients to test for COVID-19 prior to treatment with antineoplastic therapy
  18. Review consensus guidelines for resumption of antineoplastic therapy after the recovery of COVID-19 in the cancer patient

Registration

This course is complimentary to all registered attendees (please note registration is required).

By registering for this live virtual course, you will be able to view presentations, hear live audio, and interact online. CME credit will be offered for this course and a certificate will be available after a post-course evaluation is complete.

This event will be fully web-based, so all you will need is a computer, phone, or tablet and an internet connection. Access details will be emailed to all attendees before the course. 


Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.